ProBiotix Health teams up with Raff for Mexico commercial partnership

The five-year agreement enables Raff to act in partnership with ProBiotix, as the exclusive distributor of Lactobacillus plantarum LP_LDL​ to be used as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026.

According to a press release, Mexico has a population of 131 million people, with cardiovascular disease the single largest killer, accounting for nearly 24% of all deaths. In addition, it is estimated that around 3.6 million people die in Mexico every year from high cholesterol.

“After lengthy discussions, we are delighted to announce our partnership with Raff,” said Steen Andersen, CEO of ProBiotix. “We firmly believe that they share our ethos: to develop innovative products to help enrich individuals with healthier lives.

“The cardiovascular drug market in Mexico is estimated to be worth $2.2 billion this year and provides a huge latent opportunity. With an ageing population, we believe Mexico provides a highly attractive market for ProBiotix to target.”

Raff​

Founded in 1999, Raff is described as a distributor of raw materials and value-added ingredients, with a particular focus on the dairy and nutraceutical sectors.

“We are a well-established probiotics supplier in the Mexican market through our relationship with Italy-based Sacco Systems,” said Rafael Gonzalez, Commercial Director of Raff. “The opportunity to partner with ProBiotix Health, a pioneer in probiotics and cardiometabolic health, is extremely exciting for us.

“We welcome the opportunity to expand our portfolio with a unique well-documented precision biotic like LP_LDL​. We believe that LP_LDL​ fills an untapped potential in the fast-growing Mexican supplement market and that the product sits well with our already strong position in the sector.”